FWM
HZNP

Filbrandt Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Filbrandt Wealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17
Closed -$2K – 204
2021
Q1 		$2K Buy
+17
New +$1.44K ﹤0.01% 163
2020
Q2 		– Sell
-25
Closed -$1K – 485
2020
Q1 		$1K Buy
+25
New +$846 ﹤0.01% 246

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Filbrandt Wealth Management's HZNP Position: Q2 2021 in Review

Filbrandt Wealth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2021, closing a stake of 17 shares — an estimated $2K sold.

Filbrandt Wealth Management first reported a position in HZNP in Q1 2020 and held it in 2 quarters. The position peaked at $2K in Q1 2021. 526 funds tracked by Wall St. Rank hold HZNP as of Q2 2021.

  • Filbrandt Wealth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2021 after selling out during the quarter.
  • Filbrandt Wealth Management sold 17 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2021, an estimated $2K.
  • Filbrandt Wealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2020 and held it in 2 quarters.
  • Filbrandt Wealth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2K in Q1 2021.
  • 526 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2021.

Based on Filbrandt Wealth Management's 13F filing for Q2 2021, filed 7 Jul 2021.